Roku Expands Roku TV Licensing Program Into Europe
7.9.2019 11:30:00 EEST | Business Wire | Press release
IFA – Roku Inc. (NASDAQ: ROKU) today announced it is further expanding the Roku TV™ licensing program into Europe. Roku CEO Anthony Wood shared during his keynote speech that Hisense is the first European Roku TV partner and is expected to launch Roku TV models in the UK in Q4. Hisense Roku TV models combine Roku’s intuitive and easy-to-use operating system including thousands of streaming channels; with Hisense’s picture and screen technologies delivering 4K Ultra HD resolution and enhanced detail and contrast levels of HDR. Showcased this week at IFA, a world-leading consumer tech show in Berlin, attendees can see the first Hisense Roku TV for Europe in Roku’s Booth #234, Hall 26 and Hisense’s Booth #201, Hall 6.2.
TV manufacturers can license Roku TV reference designs and use the Roku OS to quickly build world-class smart TVs. Roku TV was first introduced at the 2014 Consumer Electronics Show, and today 100+ models are available from 10+ brands in North America. Roku estimates that in the first half of 2019 more than one-in-three smart TVs sold in the U.S. were Roku TVs, making the Roku OS the #1 selling smart TV OS in the U.S.
“While consumers love Roku TV’s simplicity and advanced features, TV manufacturers benefit from the low cost of manufacturing, a variety of technology options, and support from Roku. The ability to quickly bring to market a leading smart TV experience that is regularly updated by Roku and is packed with entertainment gives TV manufacturers an edge in the competitive TV business,” said Wood. “We are pleased to bring the Roku TV licensing program to Europe and look forward to the first Hisense Roku TVs in market this year.”
Simple Entertainment Experience for Consumers
Roku TV is a better smart TV. Roku TV removes the complicated layers and menus, and unnecessary features and settings that plague smart TVs today. Instead, Roku TVs feature a Roku home screen that showcases all available content sources in one place making it easy to watch live programming, stream a movie or TV show, or listen to a song in just seconds. Just like Roku streaming players, Roku TVs have full access to the Roku Channel Store filled with thousands of streaming channels that offer access to 150,000 movies and TV shows as well as live sports news, music, kids, food, science, tech, fitness, foreign language and other programming. Roku TV models can be controlled with either an included simple TV remote or with the Roku mobile app for Android and iOS devices. With the Roku mobile app consumers can stream entertainment to their Roku TV, use their voice to search for movies and TV shows, and enjoy private listening of TV audio with headphones.
Maintenance-Free, Low-Cost Smart TV Platform for Manufacturers
TV manufacturers receive the Roku TV reference platform complete with TV and remote control designs as well as technical support to manufacture and maintain the best TV experience. Meanwhile, Roku manages the entire software ecosystem for all Roku TVs which includes securing and updating streaming channels and providing frequent software updates to deliver new features and experience enhancements.
Manufacturers interested in partnering with Roku can email rokutv@roku.com
Availability and Pricing
Hisense Roku TV models are expected to bring an affordable yet enhanced viewing experience to UK consumers. Hisense Roku TV models are expected to be available for purchase in the UK in Q4 in sizes ranging up to 65 inches. Pricing and other details will be announced by Hisense later this year.
About Roku, Inc.
Roku pioneered streaming to the TV. We connect users to the streaming content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilities to engage consumers. Roku TV™ models and Roku streaming players are available around the world through direct retail sales and licensing arrangements with TV OEMs and service operators. Roku audio devices are available in the U.S.A. through direct retail sales. Roku is headquartered in Los Gatos, Calif. U.S.A.
This press release contains “forward-looking” statements that are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to the benefits and impact of the Roku OS and Roku TV models and the availability of Roku TV models in the UK and Europe. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports Roku, Inc. files with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2018 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. Copies of reports filed with the SEC are posted on Roku’s website and are available from Roku without charge.
Roku is a registered trademark and Roku TV is a trademark of Roku, Inc. in the U.S. and in other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190907005006/en/
Contact information
Roku
Mike Duin
mduin@roku.com
Axicom PR
roku@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom